Novartis stock: 5% growth outlook and Cosentyx FDA approval
Published on 11/21/2026 at 11:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWeek highlights for the drugmaker
- The FDA approval gives Cosentyx its 11th indication in the United States.
- Novartis raised peak-sales targets for Kesimpta, Scemblix and Leqvio.
- The updated strategy also points to a broad late-stage pipeline through 2031.
Novartis entered the week with a regulatory advance and ended it with a broader growth outlook. On November 17, the US Food and Drug Administration approved Cosentyx for adults with polymyalgia rheumatica who had an inadequate response to corticosteroids or could not tolerate a steroid taper, according to Novartis.
The approval makes Cosentyx the first and only anti-IL-17 biologic approved in the United States for this condition and adds the drug's 11th US indication. Novartis said the decision was based on the Phase III REPLENISH trial, in which 40.5% of patients receiving the 150-milligram dose achieved sustained remission at week 52, compared with 20.5% on placebo.
Management raises long-term targets
On November 19, Novartis said it expects net sales to grow at a 5% compound annual rate at constant currencies from 2026 through 2031. The company also said its core operating margin is on track to return to more than 40% by 2029, according to a separate Novartis announcement.
The company raised its peak-sales target for Kesimpta to 8 billion US dollars from 6 billion, Scemblix to 5 billion US dollars from 4 billion, and Leqvio to 5 billion US dollars from 4 billion. Novartis said nine marketed assets now have peak-sales potential between 3 billion and 10 billion US dollars, while more than 30 potential high-value pipeline assets support the longer-term growth plan.
Current trading level
Novartis stock last traded at 137.64 euros on Lang & Schwarz at 11:51:54 CET on Saturday, November 21, 2026.
Novartis company facts
- Company: Novartis AG
- ISIN: CH0012005267
- Last quoted price: 137.64 euros on Lang & Schwarz, November 21, 2026, 11:51:54 CET
For broader market context, see Current market reports.
